1 ic survival than mucinous adenocarcinoma and
nonmucinous adenocarcinoma patients (log-rank, P < 0.001
2 approximately 5 mm; (c) lepidic predominant
nonmucinous adenocarcinoma, representing histopathologic
3 mongst the 42 nodules of the 9 patients with
nonmucinous adenocarcinoma, the mean tumor-to-background
4 HPV DNA was not detected in any
nonmucinous adenocarcinomas including clear cell, serous
5 Nonmucinous but not mucinous tumors were significantly a
6 ding 54% (7/13) of mucinous and 63% (5/8) of
nonmucinous carcinomas.
7 carcinomas, consisting of 17 mucinous and 11
nonmucinous carcinomas.
8 urate test for differentiating mucinous from
nonmucinous cystic lesions.
9 urve (0.79) for differentiating mucinous vs.
nonmucinous cystic lesions.
10 accuracy to distinguish between mucinous and
nonmucinous cysts.
11 ability to distinguish between mucinous and
nonmucinous cysts.
12 p15.1 is strongly associated with high grade
nonmucinous epithelial ovarian cancer.
13 The main outcome was
nonmucinous epithelial ovarian cancer.
14 nocarcinoma that shows predominantly lepidic
nonmucinous growth, which at CT is usually part solid bu
15 0.82-2.52) and 1.90 (95% CI: 0.95-3.80) for
nonmucinous histology, respectively.
16 hich 1375 had mucinous histology and 860 had
nonmucinous histology.
17 h pathologically proved mucinous (n = 9) and
nonmucinous (
n = 17) rectal tumors, MR imaging was perfo
18 % are mucinous and have worse prognoses than
nonmucinous ones.
19 There were 4476 case patients with
nonmucinous ovarian cancer and 6659 control participants
20 minimally deleted regions were identified in
nonmucinous ovarian cancer.
21 Women with
nonmucinous ovarian carcinoma (n = 1,001) enrolled onto
22 hould be offered to all women diagnosed with
nonmucinous,
ovarian carcinoma, regardless of family his
23 ant adenocarcinoma are now described, all as
nonmucinous,
predominantly invasive, may include a small
24 Mucinous and
nonmucinous rectal tumors can be differentiated with MR
25 ugh overall CSS was similar for mucinous and
nonmucinous subtypes, differences in stage distribution
26 tly higher in the mucinous compared with the
nonmucinous tumors (P = .0004, P = .0008, and P = .00002
27 e odds ratio was 0.89 (95% CI 0.85-0.93) for
nonmucinous tumors and 0.98 (95% CI 0.93-1.04) for mucin
28 (95% confidence interval (CI) 0.69-0.85) for
nonmucinous tumors and 1.03 (95% CI 0.88-1.21) for mucin
29 ) was significantly and inversely related to
nonmucinous tumors but not to mucinous tumors.
30 fference in odds ratios between mucinous and
nonmucinous tumors).
31 The risk of
nonmucinous tumors, but not mucinous tumors, was positiv
32 Among women with
nonmucinous tumors, increasing trends in risk of invasiv
33 Overexpression of PAFR was found in most
nonmucinous types of ovarian cancer but not in HOSE and